ライフサイエンスコーパス: 2-deoxyglucose

1 nia) and viability (insulin-stimulated (18)F-2-deoxyglucose).

2 in the presence of the glycolysis inhibitor 2-deoxyglucose.

3 ntravenous injection of the glucopenic agent 2-deoxyglucose.

4 ncreased in Arabidopsis cells in response to 2-deoxyglucose.

5 ace of metabolic inhibition with cyanide and 2-deoxyglucose.

6 ctly different sensitivities to lysozyme and 2-deoxyglucose.

7 g RNAs inhibits insulin-stimulated uptake of 2-deoxyglucose.

8 nsitize wt cells to the glycolytic inhibitor 2-deoxyglucose.

9 g inhibition of glycolysis by iodoacetate or 2-deoxyglucose.

10 the wide-field and local organization using 2-deoxyglucose.

11 s at any of the 6 positions for transport of 2-deoxyglucose.

12 KNS42, UW479 and RES186) using metformin and 2-deoxyglucose.

13 he glucose analogs alpha-methyl glucoside or 2-deoxyglucose.

14 owth of these UOK257 cells by treatment with 2-deoxyglucose.

15 mp coupled with tracer radioactively labeled 2-deoxyglucose.

16 hy imaging with fluorine-18-labeled 2-fluoro-2-deoxyglucose ((18)FDG) ligand with kinetic analysis de

17 ive accumulation of two cytotoxic compounds, 2-deoxyglucose (2-DG) and copper(II)diacetyl-bis(N(4)-me

18 as measured autoradiographically with [(14)C]2-deoxyglucose (2-DG) and LCBF with [(14)C]iodoantipyrin

19 the rat first somatosensory cortex with [14C]2-deoxyglucose (2-DG) autoradiography in rats treated da

20 On the basis of evidence that 14C-2-deoxyglucose (2-DG) autoradiography indicates activity

21 red using [14C]iodoantipyrine (IAP) and [14C]2-deoxyglucose (2-DG) autoradiography, respectively.

22 tical activity during testing [P8; using 14C 2-deoxyglucose (2-DG) autoradiography] was assessed afte

23 tachment learning and its neural correlates [2-deoxyglucose (2-DG) autoradiography].

24 Treatment with the glycolytic blocker 2-deoxyglucose (2-DG) decreases association of the redox

25 higher uptake of radio-labeled [14C]2-fluoro-2-deoxyglucose (2-DG) in the preoptic area (25%) and sig

26 rats show fourth ventricular application of 2-deoxyglucose (2-DG) inhibits NST neurons and activates

27 Although 2-deoxyglucose (2-DG) is well characterized as a glycoly

28 ere assessed based on LCGU using the [(14)C]-2-deoxyglucose (2-DG) method.

29 glucose utilization (LCGU) using the [(14)C]-2-deoxyglucose (2-DG) method.

30 , male, Sprague-Dawley rats using the [(14)C]2-deoxyglucose (2-DG) method.

31 al glucose utilization (LCGU) using the [14C]2-deoxyglucose (2-DG) method.

32 esponses to glycemic challenges [intravenous 2-deoxyglucose (2-DG) or insulin].

33 re, we show that the hexose kinase inhibitor 2-deoxyglucose (2-dG) preferentially kills cancer cells

34 Significant differences for 2-deoxyglucose (2-DG) relative recovery at 1.0 microL/mi

35 ion and does not respond to either Ca(2+) or 2-deoxyglucose (2-DG) stimulation.

36 MK-801 were examined on regional brain [14C]-2-deoxyglucose (2-DG) uptake in rats.

37 Patterns of 2-deoxyglucose (2-DG) uptake in the glomerular layer of

38 poration into glycogen and a 30% decrease in 2-deoxyglucose (2-DG) uptake, compared with muscles incu

39 esponses and on alterations in regional [14C]2-deoxyglucose (2-DG) uptake.

40 The study objective was to determine if 2-deoxyglucose (2-DG), a glucose analogue that blocks it

41 ytes with transport rates similar to that of 2-deoxyglucose (2-DG), but due to inherent difficulties

42 ocal MAN perfusion of the glucoprivic agent, 2-deoxyglucose (2-DG), under normal and hypoglycemic con

43 , emission maximum 794 nm, was conjugated to 2-deoxyglucose (2-DG).

44 te in the nucleus in response to glucose and 2-deoxyglucose (2-DG).

45 ation of an inhibitor of glucose metabolism, 2-deoxyglucose (2-DG).

46 ve abilities upon glycolysis inhibition with 2-deoxyglucose (2-DG).

47 methoxyphenylhydrazone (FCCP, 50 nmol/L) and 2-deoxyglucose (2-DG, 10 mmol/L), there was a decrease i

48 efficacy of F1,6BP was compared with that of 2-deoxyglucose (2-DG; an inhibitor of glucose uptake and

49 MCs is reciprocally regulated by glucose and 2-deoxyglucose (2-DG; inhibitor of cellular glucose meta

50 The glucose analog 2-deoxyglucose (2-DOG) reduced ROS to levels found in no

51 98059; and (c) effects of AICAR on aPKCs and 2-deoxyglucose (2-DOG) uptake were inhibited by genistei

52 y was assessed via measurement of zero-trans 2-deoxyglucose (2-DOG) uptake.

53 ochlearis muscles were incubated with [(3)H]-2-deoxyglucose (2DG) +/- 100 microU/ml insulin.

54 ltiple brain structures during neglect using 2-deoxyglucose (2DG) as a metabolic marker of neural act

55 Conversely, 2-deoxyglucose (2DG) blocked glycolysis and partially in

56 llowing exposure using uptake of 14C-labeled 2-deoxyglucose (2DG) in quiet.

57 The glucose analog 2-deoxyglucose (2DG) inhibits the growth of Saccharomyce

58 After 15 min, the quantified 2-deoxyglucose (2DG) method was carried out in freely be

59 Then, we used [(14)C]2-deoxyglucose (2DG) uptake and single-neuron recording

60 nsitizing effect of CR, we measured in vitro 2-deoxyglucose (2DG) uptake in the presence and absence

61 tions of primary visual cortex and measuring 2-deoxyglucose (2DG) uptake to assess neural activity in

62 2-Deoxyglucose (2DG) uptake was measured in isolated sol

63 Rates of muscle 2-deoxyglucose (2DG) uptake were determined by measuring

64 lateral neuronal and hemodynamic changes and 2-deoxyglucose (2DG) uptake, as measured by autoradiogra

65 cose was replaced with 5 mM acetate and 5 mM 2-deoxyglucose (2DG), and hexose transport was measured

66 d the impact of glycolysis inhibition, using 2-deoxyglucose (2DG), in combination with cytotoxic agen

67 ll metabolism with the glycolysis inhibitor, 2-deoxyglucose (2DG), is a viable therapeutic strategy,

68 Pharmacological doses of glucose analog, 2-deoxyglucose (2DG), is an alternative glucoprivic agen

69 se withdrawal or glycolytic inhibition using 2-deoxyglucose (2DG).

70 The glucose analog 2-deoxyglucose (2dGlc) inhibits the growth and multicell

71 These effects were mimicked by 8 g/l 2-deoxyglucose (2DOG) (transported, phosphorylated but n

72 We used a 2-deoxyglucose (2DOG) energy clamp to set DeltaPsi at fi

73 on, we used pharmacological agents (insulin, 2-deoxyglucose, 3-nitropropionic acid, and kainic acid)

74 ild-type and GLUT1-overexpressing mice using 2-deoxyglucose, 3-O-methylglucose, and the 2-N-[4-(1-azi

75 ort was significantly decreased by including 2-deoxyglucose (5 mM) in the uptake medium.

76 was measured from the rate of production of 2-deoxyglucose 6-phosphate (2DG6P), using (31)P nuclear

77 scopy measuring 2-deoxyglucose conversion to 2-deoxyglucose-6-phosphate, was measured in isolated per

78 ylates 2dGlc to form the toxic intermediate, 2-deoxyglucose-6-phosphate.

79 The activity of compounds with 2-deoxyglucose (8 and 9) > compounds with 2,6-deoxygluco

80 Similarly, in cancer cells OLIG and 2-deoxyglucose, a glycolytic inhibitor, depolarized mito

81 In turn, 2-deoxyglucose, a non-metabolizable glucose analogue, el

82 RESULTS- We show that 1) 2-deoxyglucose, a nonmetabolizable glucose analog, mimic

83 Insulin-stimulated [(3)H]2-deoxyglucose accumulation was measured in collagenase-

84 nt degrees of overlap in their monomolecular 2-deoxyglucose activation patterns to test the theory in

85 dily enter torpor in response to fasting and 2-deoxyglucose administration.

86 ucose analogs such as 3-O-methyl-glucose and 2-deoxyglucose also caused an induction, suggesting that

87 The cells were highly sensitive to 2-deoxyglucose, an inhibitor of glycolysis and proposed

88 using two-photon imaging of a near-infrared 2-deoxyglucose analogue (2DG-IR), that glucose is taken

89 ith glucose deprivation combined with 0.5 mm 2-deoxyglucose and 5 mm azide ("chemical ischemia") to m

90 zolidinedione-derived ERMA, CG-12, vis-a-vis 2-deoxyglucose and glucose deprivation, we obtain eviden

91 ferences in the insulin-stimulated uptake of 2-deoxyglucose and in the activity of carnitine palmitoy

92 st rhythms in uptake of the metabolic marker 2-deoxyglucose and in their content of neurotrophins.

93 were decreased by the glucose antimetabolite 2-deoxyglucose and increased by high blood glucose conce

94 ropionate) as well as glycolytic inhibitors (2-deoxyglucose and iodoacetate) on the induction and mai

95 Secretion was inhibited by 2-deoxyglucose and iodoacetate, confirming active secret

96 cell death in response to the combination of 2-deoxyglucose and metformin.

97 In the presence of 2-deoxyglucose and NaN3, amino acids were unable to stim

98 cells are 10 and 4.9 times more sensitive to 2-deoxyglucose and oxamate, respectively, than wt cells.

99 Moreover, the glycolysis inhibitors, 2-deoxyglucose and oxamate, selectively inhibited the gr

100 found that ABT-263 increased sensitivity to 2-deoxyglucose and promoted rapid and extensive cell dea

101 In vitro, 2-deoxyglucose and radiation synergistically up-regulate

102 in the presence of the glycolysis inhibitor 2-deoxyglucose and radiation treatment followed by PBMC

103 the synergy between the glycolytic inhibitor 2-deoxyglucose and rapamycin in decreasing cell viabilit

104 ld be mimicked with the glycolytic inhibitor 2-deoxyglucose and reversed with a pyruvate analogue.

105 th a combination of the metabolic inhibitors 2-deoxyglucose and rotenone, 100 mM K(+) media- or hypot

106 process, because cells depleted of ATP with 2-deoxyglucose and sodium azide were unable to properly

107 Using this knowledge we identified 2-deoxyglucose and temsirolimus as agents that can be ad

108 Uptake of 2-deoxyglucose and various indexes of oxidative and glyc

109 rular layer was measured as uptake of [(14)C]2-deoxyglucose and was mapped into anatomically standard

110 e patterns were measured as uptake of [(14)C]2-deoxyglucose and were mapped into standardized data ma

111 vity (euglycemic-hyperinsulinemic clamp with 2-deoxyglucose) and fat utilization during 1 h of exerci

112 In HeLa and A549 cells, mannitol, 2-deoxyglucose, and ionomycin, but not 5-aminoimidazole-

113 , mannosamine, Glc, GlcNAc, GalNAc, mannose, 2-deoxyglucose, and oligosaccharides of chitosan.

114 Furthermore, 2-deoxyglucose- and ionomycin-stimulated AMPK activity,

115 We used 2-deoxyglucose autoradiographic mapping of neural activi

116 We have used both single- and double-label 2-deoxyglucose autoradiographic methods to image the pat

117 using c-Fos early gene expression and (14)C 2-deoxyglucose autoradiography during mother-to-infant f

118 as stimulation-evoked cortical activity (14C 2-deoxyglucose autoradiography) was detectable only in P

119 ormed 13-15 days after lesioning using [14]C-2-deoxyglucose autoradiography.

120 y tumors had similar uptake of [(18)F]fluoro-2-deoxyglucose before and after 2 weeks of 2-DG treatmen

121 Inhibition of hexokinase with 2-deoxyglucose blocked the transforming activity of CBL

122 glucosensors detect mannose, d-glucose, and 2-deoxyglucose but not galactose, l-glucose, alpha-methy

123 Hydralazine activated more neurons than 2-deoxyglucose but similar numbers of catecholaminergic

124 ed by the non-metabolizable glucose analogue 2-deoxyglucose, but not by stimulating intracellular ATP

125 enuated by fructose, galactose, mannose, and 2-deoxyglucose, but not by the non-metabolizable glucose

126 embles that of cortical metabolism seen with 2-deoxyglucose, but the increase in vascular density pre

127 nterregulatory responses to hypoglycemia and 2-deoxyglucose, but the mechanisms that mediate these re

128 e neurons shortly after vascular insulin and 2-deoxyglucose challenges.

129 -(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-2 deoxyglucose compared with those from HIV(-) controls.

130 transgenic mice exhibited reduced uptake of 2-deoxyglucose compared with muscles isolated from contr

131 d low uptake activity for the glucose analog 2-deoxyglucose, consistent with a role in the transport

132 ar magnetic resonance spectroscopy measuring 2-deoxyglucose conversion to 2-deoxyglucose-6-phosphate,

133 Systemic administration of 2-deoxyglucose depleted ADR content in control rats, and

134 Addition of 5 mM 2-deoxyglucose did not restore glycogen synthase translo

135 operazine, a combination of sodium azide and 2-deoxyglucose, EDTA, incubation at 4 degrees C, or trea

136 the presence of an inhibitor of glycolysis, 2-deoxyglucose, enhanced the generation of memory cells

137 d quantitatively by measuring uptake of [14C]2-deoxyglucose evoked by each odorant.

138 ompare the neuronal populations activated by 2-deoxyglucose evoked glucoprivation.

139 [18F]2-fluoro-2-deoxyglucose (FDG) -positron emission tomography (PET)

140 s evaluated in relationship to 2-[18F]fluoro-2-deoxyglucose (FDG) as an oncological probe in cultured

141 [(18)F]-2-Fluoro-2-deoxyglucose (FDG) is a glucose analog currently utili

142 olism was assessed with (18)F-labeled fluoro-2-deoxyglucose (FDG) positron emission tomography in 236

143 state have shown regionally increased (18)F-2-deoxyglucose (FDG) uptake with a marked transmural gra

144 uantify regional function, perfusion and 18F-2-deoxyglucose (FDG) uptake.

145 unctional regions, but the deposition of 18F-2-deoxyglucose (FDG) varied.

146 n [glucose](ablumen), influx of radiolabeled 2-deoxyglucose from lumen to the abluminal compartment w

147 easures derived from the comparison of [14C]-2-deoxyglucose glomerular activity pattern data yielded

148 ilia and knob can incorporate and accumulate 2-deoxyglucose (glucose analog), but not when blocking G

149 ensitivity to radiation with or without 25mM 2-deoxyglucose (glycolytic inhibitor) was evaluated in c

150 SF188 cells were highly sensitive to 2-deoxyglucose however, combination of metformin with 2-

151 perceptual similarity and comparability with 2-deoxyglucose imaging data from the olfactory bulb are

152 C-fos immunohistochemistry and [14C]2-deoxyglucose imaging identified brain structures invol

153 The uptake of 2-deoxyglucose in MIN6 cells was similarly inhibited (IC

154 metic agents (ERMAs) such as resveratrol and 2-deoxyglucose in suppressing carcinogenesis in animal m

155 Addition of 10 mM 2-deoxyglucose in the absence of exogenous energy supply

156 nt enantiomers based on the uptake of [(14)C]2-deoxyglucose in the olfactory bulb glomerular layer.

157 Injection of 2-deoxyglucose induced a very rapid sympathoadrenal resp

158 In contrast, the glycolytic inhibitor 2-deoxyglucose induced prosurvival autophagy.

159 he two glucose analogs 3-O-methylglucose and 2-deoxyglucose, induced greater steady-state levels of t

160 Addition of 2-deoxyglucose inhibited seed germination, but did so le

161 ividual tissues was estimated using [1-(14)C]2-deoxyglucose injection during the clamp.

162 tire layer was assessed by mapping uptake of 2-deoxyglucose into anatomically standardized data matri

163 ivation of AMPK in response to ionomycin and 2-deoxyglucose is not impaired in LKB1(-/-) murine embry

164 exposure to kainic acid or potassium cyanide/2-deoxyglucose (KCN/2-DG) for varying lengths of time, a

165 e animals studied using the metabolic marker 2-deoxyglucose, layer 4 was 25% denser than the other la

166 king p53, we showed that CR mimetics such as 2-deoxyglucose led to a decrease in Mcl-1 expression and

167 and pdk1, lung fluorine-18-labeled 2-fluoro-2-deoxyglucose ligand uptake was significantly increased

168 synthesis (oligomycin, 2,4-dinitrophenol, or 2-deoxyglucose) made them more susceptible to cell death

169 results fail to confirm predictions based on 2-deoxyglucose maps of bulbar activity that enantiomers

170 [(14)C] 2-deoxyglucose maps to investigate patterns of glucose u

171 To this end, we used the [14C]2-deoxyglucose method to determine glomerular responses

172 tructures in this system, we used the [(14)C]2-deoxyglucose method to determine glomerular responses

173 By using the (14C)2-deoxyglucose method, inhibition has been shown to be a

174 th and glycolysis (as measured by (18)fluoro-2-deoxyglucose microPET) of glioblastoma xenografts engi

175 2-Deoxyglucose (MW approximately 180), inulin (MW approx

176 ine, loxapine and risperidone indicated that 2-deoxyglucose non-competitively antagonized the inhibit

177 effects of metabolic blockade (cyanide plus 2-deoxyglucose) on Ca2+ release from the sarcoplasmic re

178 Compounds, such as 2-deoxyglucose or 6-aminonicotinamide, that reduced the

179 Inhibiting glycolysis by 2-deoxyglucose or iodoacetate, in the presence of glucos

180 e directly inhibited glycolysis using either 2-deoxyglucose or iodoacetic acid.

181 caspase-dependent cell death in response to 2-deoxyglucose or its combination with metformin.

182 lls, Thr49 was phosphorylated in response to 2-deoxyglucose or phenformin, stimuli that activate the

183 sion, protected against apoptosis induced by 2-deoxyglucose or staurosporine, as assessed by terminal

184 This increase was blocked by either 2-deoxyglucose or the protein phosphatase inhibitor, cal

185 olysis brought about by glucose deprivation, 2-deoxyglucose, or Akt inhibition.

186 ls were exposed to the glycolytic inhibitor, 2-deoxyglucose, or fatty acid synthase inhibitors to per

187 4 cell lines, 5 small-molecule perturbagens (2-deoxyglucose, oxamate, oligomycin, rapamycin, and wort

188 on between increased normalized (18)F fluoro-2-deoxyglucose PET SUVmax, outcome, and EMT in NSCLC.

189 [(18)F]fluoro-2-deoxyglucose-PET (FDG-PET) can visualize a small tumou

190 Glucosamine, 2-deoxyglucose, phloridzin, and iodoacetic acid blocked

191 We retrospectively evaluated (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) sc

192 et that contained fluorine 18 ((18)F) fluoro-2-deoxyglucose positron emission tomography (PET) and me

193 Using 18FDG (18fluoro-2-deoxyglucose) positron emission tomography, we found t

194 e analogs such as methyl alpha-glucoside and 2-deoxyglucose, resided in a substitution of G in ptsG-I

195 llular responses relative to resveratrol and 2-deoxyglucose, respectively.

196 In addition, treatment of NOD mice with 2-deoxyglucose resulted in improved beta cell granularit

197 studies using intrinsic optical imaging and 2-deoxyglucose) resulted in increased detection threshol

198 ucose however, combination of metformin with 2-deoxyglucose significantly reduced cell proliferation

199 pendent manner, whereas oxidative stress and 2-deoxyglucose stimulated phosphorylation at this site v

200 2-deoxyglucose stimulated Thr49 phosphorylation of endog

201 ysis, functional magnetic resonance imaging, 2-deoxyglucose studies, and induction of gene expression

202 maging with positron emission tomography and 2-deoxyglucose studies.

203 n of pyruvate or alpha-ketocaproate, but not 2-deoxyglucose, suggesting that mitochondrial metabolism

204 We demonstrate that the parthenolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a p

205 as determined by NMR spectroscopy, including 2-deoxyglucose, the glucose analogue used for tumor dete

206 When prediabetic NOD mice were treated with 2-deoxyglucose to block aerobic glycolysis, there was a

207 d of ATP by the addition of sodium azide and 2-deoxyglucose to block ATP production by oxidative phos

208 ere, we show that low doses of verapamil and 2-deoxyglucose, to accentuate the cost of resistance and

209 Is was screened for their ability to inhibit 2-deoxyglucose transport in primary rat adipocytes.

210 of maximal insulin (10(-7) mol/l)-stimulated 2-deoxyglucose transport was reduced by 32% (P < 0.05) i

211 time- and concentration-dependent decline in 2-deoxyglucose transport.

212 tion preconditioning (1 h of antimycin A and 2-deoxyglucose treatment followed by 1 h of recovery), a

213 ing p38 vectors reduced apoptosis induced by 2-deoxyglucose treatment, whereas overexpression of wild

214 1,6-bisphosphate or the metabolic inhibitor 2-deoxyglucose, two agents that disrupt the interaction

215 ucose tracer analogs, uniformly labeled [14C]2-deoxyglucose ([U-14C]2DG) and FDG, are widely used to

216 o assessments of cold-induced changes in BAT 2-deoxyglucose uptake (increased 2.7-fold), BAT lipogene

217 sulted in increased glycolysis and increased 2-deoxyglucose uptake (P < 0.05).

218 Expression of UCP3 in L6 myotubes increased 2-deoxyglucose uptake 2-fold and cell surface GLUT4 2.3-

219 mice, caCaMKKalpha increased in vivo [(3)H]-2-deoxyglucose uptake 2.5-fold and AMPKalpha1 and -alpha

220 oocytes, and their membrane concentrations, 2-deoxyglucose uptake activities, and sensitivities to p

221 us oocytes, and its plasma membrane content, 2-deoxyglucose uptake activity, and sensitivity to pCMBS

222 oocytes and its steady-state protein level, 2-deoxyglucose uptake activity, and sensitivity to pCMBS

223 its N terminus suppressed insulin-stimulated 2-deoxyglucose uptake and Glut4 translocation to roughly

224 t substantially inhibited insulin-stimulated 2-deoxyglucose uptake and GLUT4 translocation.

225 in insulin signaling and insulin-stimulated 2-deoxyglucose uptake and glycogen synthesis.

226 hibitor LY-294002 display a decrease in both 2-deoxyglucose uptake and hexokinase activity as compare

227 ly significant correlation between posterior 2-deoxyglucose uptake and molecular properties associate

228 endogenously generating circadian rhythms in 2-deoxyglucose uptake and Per gene expression.

229 this manifested as improved insulin-mediated 2-deoxyglucose uptake and suppression of lipolysis.

230 caCaMKKalpha increased basal in vivo [(3)H]-2-deoxyglucose uptake approximately twofold, insulin inc

231 ent with DMOG or DHB reverses the decline in 2-deoxyglucose uptake caused by NGF withdrawal and suppr

232 itron emission tomography of 2-[(18)F]fluoro-2-deoxyglucose uptake combined with computed tomography.

233 om Cip4-null mice exhibited increased [(14)C]2-deoxyglucose uptake compared with cells from wild-type

234 d by individual odorant chemicals, we mapped 2-deoxyglucose uptake during exposures to vapors arising

235 scles with the greatest UBX-Cter expression, 2-deoxyglucose uptake during fasting was similar to that

236 letal muscle glucose transport determined by 2-deoxyglucose uptake during hyperinsulinemic-euglycemic

237 infusion rate and 90% greater muscle [(3)H]-2-deoxyglucose uptake during hyperinsulinemic-euglycemic

238 previous studies, we mapped glomerular layer 2-deoxyglucose uptake evoked by hundreds of both systema

239 In past studies in which we mapped 2-deoxyglucose uptake evoked by systematically different

240 ned with c-Fos immunohistochemistry and [14C]2-deoxyglucose uptake implicate a prominent involvement

241 Measurement of 2-deoxyglucose uptake in a Xenopus oocyte expression sys

242 Measurement of 2-deoxyglucose uptake in a Xenopus oocyte expression sys

243 progressive but similar levels of increased 2-deoxyglucose uptake in macrophages that reached up to

244 ced large differences in spatial patterns of 2-deoxyglucose uptake in posterior parts of the bulb.

245 We first investigated glomerular patterns of 2-deoxyglucose uptake in response to aromatic compounds

246 days failed to affect the increase in muscle 2-deoxyglucose uptake in response to treadmill exercise.

247 stent with the 2.5- to threefold increase in 2-deoxyglucose uptake in skeletal muscle, heart, and whi

248 tically different spatial patterns of [(14)C]2-deoxyglucose uptake in the glomerular layer of the olf

249 take in transfected muscles, we measured [3H]2-deoxyglucose uptake in vivo following intravenous gluc

250 The basal rate of 2-deoxyglucose uptake increased by 3-fold in LVH, which

251 antified activity patterns by mapping [(14)C]2-deoxyglucose uptake into anatomically standardized dat

252 In vivo 2-[(18)F]fluoro-2-deoxyglucose uptake into brown adipose tissue (BAT) wa

253 n glucose infusion rate and markedly reduced 2-deoxyglucose uptake into skeletal muscle (85-90%) and

254 lative to WL5, submaximal insulin-stimulated 2-deoxyglucose uptake into the epitrochlearis muscle was

255 odrug triester 70 did induce enhancements in 2-deoxyglucose uptake into two different cell lines with

256 nce together with impaired exercise-mediated 2-deoxyglucose uptake into white but not red muscles.

257 ed robust and surprisingly focal patterns of 2-deoxyglucose uptake involving clusters of neighboring

258 GLUT4 expression and 2-deoxyglucose uptake levels were normalized in fast-twi

259 n the ability of insulin to stimulate either 2-deoxyglucose uptake or the translocation of GLUT4 or G

260 Ischemia stimulated a 2.5-fold increase in 2-deoxyglucose uptake over base line in WT, whereas the

261 erozygote matings exhibited reduction of the 2-deoxyglucose uptake rate: one by 50% (presumed heteroz

262 rular layer by using a high-resolution [14C]-2-deoxyglucose uptake technique.

263 vely active cdc42 (CA-cdc42; V12) stimulated 2-deoxyglucose uptake to 56% of the maximal insulin resp

264 Muscle 2-deoxyglucose uptake was similarly reduced under these

265 e activity of the alpha2 isoform of AMPK and 2-deoxyglucose uptake were assessed in incubated rat ext

266 h no significant changes in AMPK activity or 2-deoxyglucose uptake were detected.

267 Insulin effects on PKC-zeta/lambda and 2-deoxyglucose uptake were diminished by approximately 5

268 G(q), and CA-cdc42 on GLUT4 translocation or 2-deoxyglucose uptake were inhibited by microinjection o

269 erentiated adipocytes and insulin-stimulated 2-deoxyglucose uptake were slightly lower than in adipoc

270 closely with decreases in glucose transport (2-deoxyglucose uptake), measured during a subsequent 20-

271 e testing, measurement of in vivo myocardial 2-deoxyglucose uptake, and echocardiography were perform

272 FosB immunoreactivity, 2-deoxyglucose uptake, and firing activity of LHb were s

273 adipocytes, we analyzed Akt phosphorylation, 2-deoxyglucose uptake, and Glut4 translocation by immuno

274 0(CAAX) fully stimulated p70 S6 kinase, Akt, 2-deoxyglucose uptake, and Ras, whereas, p110(WT) had li

275 one provoked increases in insulin-stimulated 2-deoxyglucose uptake, PKC-zeta/lambda enzyme activity a

276 etely reversed defects in insulin-stimulated 2-deoxyglucose uptake, PKCzeta/lambda enzyme activity an

277 t and only slightly inhibited SNP-stimulated 2-deoxyglucose uptake, whereas L-NMMA did not inhibit co

278 sing a hyperinsulinemic-euglycemic clamp and 2-deoxyglucose uptake.

279 nsporter-4 accumulation, and enhanced [(3)H]-2-deoxyglucose uptake.

280 e dose-response curve for insulin stimulated 2-deoxyglucose uptake.

281 in-stimulated GLUT4 translocation as well as 2-deoxyglucose uptake.

282 ition, gACRP30 caused a 1.5-fold increase in 2-deoxyglucose uptake.

283 -NMMA did not inhibit contraction-stimulated 2-deoxyglucose uptake.

284 tated glucose transport as measured by [(3)H]2-deoxyglucose uptake.

285 ntraction both had fully additive effects on 2-deoxyglucose uptake.

286 T4 to the plasma membrane and stimulation of 2-deoxyglucose uptake.

287 LUT4), and exhibit highly insulin-responsive 2-deoxyglucose uptake.

288 matory activation and uptake of radiolabeled 2-deoxyglucose was assessed before and after GM-CSF expo

289 Rather, IRF3 activation by tunicamycin and 2-deoxyglucose was inhibited by 4-(2-aminoethyl)-benzene

290 At the end of the clamp, [14C]-2-deoxyglucose was injected to determine tissue-specific

291 Uptake of 3H-2-deoxyglucose was measured over 5 min and the data were

292 TP depletion, equivalent ATP loss induced by 2-deoxyglucose was without toxicity, arguing that bioene

293 n cancer cells to ERMAs, including CG-12 and 2-deoxyglucose, we demonstrated that this beta-TrCP accu

294 -(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-2 deoxyglucose were analyzed by flow cytometry on monocy

295 Glycogen synthesis and uptake of 2-deoxyglucose were reduced in skeletal muscle, suggesti

296 ocked by the energy poisons sodium azide and 2-deoxyglucose, whereas staining of the nucleus (nucleol

297 strated by using an inhibitor of glycolysis, 2-deoxyglucose, which almost totally abolished low-dose

298 glucose-inhibited neurons were activated by 2-deoxyglucose, which also activates counterregulatory r

299 de form glucose, the nonmetabolizable sugars 2-deoxyglucose, which is still converted to G-6-P as wel

300 h radiation response after administration of 2-deoxyglucose, which significantly (p<0.05) potentiated